Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly EBITDA Margin of 101685.71% in Q4 2025, down 307.59% on a QoQ basis from 24948.0% in Q3 2025, and down 9622734.0% YoY from N/an in Q4 2024.
Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported EBITDA Margin for 5 consecutive years, with 101685.71% the latest figure, recorded in Q4 2025.
- EBITDA Margin for Q4 2025 came in at 101685.71%, down 9622734.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 7794.47% (down 151364.0% YoY), and the FY2025 annual result was 7794.47%, down 151364.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 101685.71%, down from 24948.0% in the prior quarter.
- The five-year high for EBITDA Margin was 2548.08% in Q1 2022, with the low at 137772.73% in Q4 2022.
- A 5-year average of 23017.71% and a median of 4931.81% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin tumbled 13274025 bps in 2022 and soared 12648711 bps in 2023, its largest moves.
- Lyra Therapeutics' EBITDA Margin stood at 5032.47% in 2021, then slumped by 2638 bps to 137772.73% in 2022, then surged by 92 bps to 11285.62% in 2023, then surged by 52 bps to 5458.37% in 2024, then sank by 1763 bps to 101685.71% in 2025.
- The last three EBITDA Margin figures came in at 101685.71% (Q4 2025), 24948.0% (Q3 2025), and 4822.95% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -101,685.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -101,685.71% |
| Sep 30, 2025 | -24,948.00% |
| Jun 30, 2025 | -4,822.95% |
| Mar 31, 2025 | -4,831.15% |
| Dec 31, 2024 | -5,458.37% |
| Sep 30, 2024 | -6,380.51% |
| Jun 30, 2024 | -8,189.63% |
| Mar 31, 2024 | -4,421.80% |
| Dec 31, 2023 | -11,285.62% |
| Sep 30, 2023 | -3,093.20% |
| Jun 30, 2023 | -3,603.28% |
| Mar 31, 2023 | -4,222.68% |
| Dec 31, 2022 | -137,772.73% |
| Sep 30, 2022 | -4,129.81% |
| Jun 30, 2022 | -2,742.86% |
| Mar 31, 2022 | -2,548.08% |
| Dec 31, 2021 | -5,032.47% |
| Sep 30, 2021 | -79,150.00% |